On April 7, 2021 TriSalus Life Sciences reported that The American Association for Cancer Research (AACR) (Free AACR Whitepaper) will host its annual meeting, AACR (Free AACR Whitepaper) 2021, virtually, over two weeks: April 10-15 and May 20-26 (Press release, TriSalus Life Sciences, APR 7, 2021, View Source [SID1234577888]). The meeting program covers the latest discoveries across the spectrum of cancer research and highlights the work of the best minds in research and medicine from institutions all over the world.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 7, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported that Chief Executive Officer, Gil Beyen, will participate in the following conferences in the month of April and engage in select one-on-one investor meetings alongside members of the senior management (Press release, ERYtech Pharma, APR 7, 2021, View Source [SID1234577740]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SMALLCAP EVENT- CF&B Communication – April 14-15, 2021

Gil Beyen, Chief Executive Officer, will participate in one-on-one meetings from 8am to 1pm ET (02:00pm to 07:00pm CEST). For more information about the CF&B Communication’s SMALLCAP EVENT, please refer to the CF&B website: View Source

Kempen & Co. Life Sciences Conference – 2021 Thematic Virtual Series – April 28, 2021

Gil Beyen, Chief Executive Officer, Iman El-Hariry, Chief Medical Officer, and Eric Soyer Chief Financial Offier will participate in one-on-one meetings, small group meetings and showcase sessions from 8am to 2pm ET (02:00pm to 08:00pm CEST). For more information about the Kempen & Co Life Sciences Conference Series, please refer to the Kempen conference website: View Source

If you are interested in arranging a one-on-one meeting, please contact your conference representative or contact Corey Davis at LifeSciAdvisors.

On April 7, 2021 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported the pricing of an underwritten public offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share (Press release, Crinetics Pharmaceuticals, APR 7, 2021, View Source [SID1234577728]). All of the shares to be sold in the offering are being sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. The offering is expected to close on or about April 12, 2021, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Crinetics intends to use the net proceeds from the proposed offering to fund the development of paltusotine and its other research and development programs, and for working capital and general corporate purposes.

SVB Leerink is acting as sole bookrunning manager for the offering.

The securities described above are being offered by Crinetics pursuant to a shelf registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement relating to this offering will be filed with the SEC. The offering may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525, ext. 6105 or by email at [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

On April 7, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, reported the grant of patent number EP3317301 entitled "Combination therapies comprising antibody molecules to LAG-3" by the European Patent Office (Press release, Immutep, APR 7, 2021, View Source [SID1234577719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG. In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer.

The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 28 July 2036.

About IMP701 and LAG525

IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.) to target LAG-3. This antagonist antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg). The antibody works to both activate effector T cells (by blocking inhibitory signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevents T cells from responding to antigen stimulation. The antibody therefore removes two brakes that prevent the immune system from responding to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T cell pathway.

Rights to the development and commercialisation of IMP701 are exclusively licensed to Novartis.

LAG525, a humanised form of IMP701 is being evaluated by Novartis in several Phase I and/or Phase II clinical trials in combination with Novartis’ PD-1 inhibitor spartalizumab for the treatment of certain cancer(s). Novartis has full responsibility for the continued development of the LAG-3 antibody program and Immutep is eligible to receive development-based milestone payments and sales-based royalties.

On April 7, 2021 Bridge Biotherapeutics, a research and development company for innovative new drugs, reported that the first phase of clinical trials for BBT-176, a candidate for the next-generation lung cancer target anticancer drug, began in earnest, and that it was administered to patients participating in the clinical trial on the 2nd (Press release, Bridge Biotherapeutics, APR 7, 2021, View Source;pn=6&sn=1&idx=64 [SID1234577708]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BBT-176 is a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) targeting the C797S specific EGFR mutation. The C797S mutation is known as an acquired resistance mutation that appears after treatment with tagriso (ingredient name: osimertinib) in Non-small Cell Lung Cancer (NSCLC). Bridge Biotherapeutics has secured data related to the tumor suppression effect of brain metastasis, including the tumor suppression effect against the C797S positive triple mutation in animal models, through the preclinical development previously advanced.

This clinical trial, which is first initiated by three domestic institutions, targets patients with locally advanced or metastatic non-small cell lung cancer with an EGFR mutation. ) We plan to closely grasp patient group data by mutation by applying procedures, etc.

BBT-176 In the first phase of clinical phase 1/2, the Dose Escalation Study evaluates the safety and tolerability of the drug to be tested to determine the recommended phase 2 dose. Next, in the Dose Expansion Study, which is expected to enter Korea and the United States within this year, ▲ Objective Response Rate (ORR), ▲ Objective Response Rate (ORR) according to version 1.1 of the Solid Tumor Response Assessment (RECIST) ; Duration of Response) and ▲ Progress-free Survival (PFS). The clinical trial is planned to be conducted on about 90 patients.

Bridge Biotherapeutics CEO Jeong-gyu Lee said, "I think it is meaningful to be the first to start the clinical trial of BBT-176, a new anticancer drug candidate targeting C797S mutant non-small cell lung cancer, in Korea, which has no treatment options worldwide." Based on the development strategy, the entire development team will do their best to conduct the clinical trials with full accuracy and speed based on the development strategy. I will add it."

More detailed information related to the BBT-176 clinical trial, which was launched this time , can be found in the Clinical Trial Information menu in the Korea Food and Drug Administration’s Integrated Drug Information System website .

On the other hand, Bridge Biotherapeutics, which started to discover its own candidates this year, started to discover and develop new candidates for non-small cell lung cancer drugs that can effectively meet various unmet medical demands, including C797S double mutation.